Decision: Favourable

Decisions Table

Study Title:

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

  • NREC Code:

    21-NREC-CT-048

  • Decision:

    Favourable

  • Meeting Date:

    11/08/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Jarushka Naidoo

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Mirati Therapeutics, Inc.

Scroll to Top